These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19745236)

  • 21. Design of Adverse Drug Events-Scorecards.
    Marcilly R; Chazard E; Beuscart-Zéphir MC; Hackl W; Băceanu A; Kushniruk A; Borycki EM
    Stud Health Technol Inform; 2011; 164():377-81. PubMed ID: 21335740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extraction of adverse drug effects from clinical records.
    Aramaki E; Miura Y; Tonoike M; Ohkuma T; Masuichi H; Waki K; Ohe K
    Stud Health Technol Inform; 2010; 160(Pt 1):739-43. PubMed ID: 20841784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents.
    Cohen AL; Budnitz DS; Weidenbach KN; Jernigan DB; Schroeder TJ; Shehab N; Pollock DA
    J Pediatr; 2008 Mar; 152(3):416-21. PubMed ID: 18280852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A data-driven method to detect adverse drug events from prescription data.
    Zhan C; Roughead E; Liu L; Pratt N; Li J
    J Biomed Inform; 2018 Sep; 85():10-20. PubMed ID: 30016721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High rates of adverse drug events in a highly computerized hospital.
    Nebeker JR; Hoffman JM; Weir CR; Bennett CL; Hurdle JF
    Arch Intern Med; 2005 May; 165(10):1111-6. PubMed ID: 15911723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with a trigger tool for identifying adverse drug events among older adults in ambulatory primary care.
    Singh R; McLean-Plunckett EA; Kee R; Wisniewski A; Cadzow R; Okazaki S; Fox C; Singh G
    Qual Saf Health Care; 2009 Jun; 18(3):199-204. PubMed ID: 19468002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying hospital admissions due to adverse drug events using a computer-based monitor.
    Jha AK; Kuperman GJ; Rittenberg E; Teich JM; Bates DW
    Pharmacoepidemiol Drug Saf; 2001; 10(2):113-9. PubMed ID: 11499849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication safety program reduces adverse drug events in a community hospital.
    Cohen MM; Kimmel NL; Benage MK; Cox MJ; Sanders N; Spence D; Chen J
    Qual Saf Health Care; 2005 Jun; 14(3):169-74. PubMed ID: 15933311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An empirical model to estimate the potential impact of medication safety alerts on patient safety, health care utilization, and cost in ambulatory care.
    Weingart SN; Simchowitz B; Padolsky H; Isaac T; Seger AC; Massagli M; Davis RB; Weissman JS
    Arch Intern Med; 2009 Sep; 169(16):1465-73. PubMed ID: 19752403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient safety: detection and prevention of adverse drug events.
    Beuscart R; McNair P; Darmoni SJ; Koutkia V; Maglaveras N; Beuscart-Zephir MC; Nohr C;
    Stud Health Technol Inform; 2009; 150():968-71. PubMed ID: 19745457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient safety through intelligent procedures in medication: the PSIP project.
    Beuscart R; McNair P; Brender J;
    Stud Health Technol Inform; 2009; 148():6-13. PubMed ID: 19745230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Costs of intravenous adverse drug events in academic and nonacademic intensive care units.
    Nuckols TK; Paddock SM; Bower AG; Rothschild JM; Fairbanks RJ; Carlson B; Panzer RJ; Hilborne LH
    Med Care; 2008 Jan; 46(1):17-24. PubMed ID: 18162851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A classification framework for exploiting sparse multi-variate temporal features with application to adverse drug event detection in medical records.
    Bagattini F; Karlsson I; Rebane J; Papapetrou P
    BMC Med Inform Decis Mak; 2019 Jan; 19(1):7. PubMed ID: 30630486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of human factors for the review of automatically detected ADE.
    Leroy N; Luyckx M; Lecocq P; Marcilly R; Beuscart-Zéphir MC
    Stud Health Technol Inform; 2009; 148():170-80. PubMed ID: 19745248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse drug event reporting in intensive care units: a survey of current practices.
    Kane-Gill SL; Devlin JW
    Ann Pharmacother; 2006; 40(7-8):1267-73. PubMed ID: 16849619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use.
    Page RL; Ruscin JM
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):297-305. PubMed ID: 17296535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Automated detection of adverse events in children.
    Lemon V; Stockwell DC
    Pediatr Clin North Am; 2012 Dec; 59(6):1269-78. PubMed ID: 23116524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay.
    Oderda GM; Said Q; Evans RS; Stoddard GJ; Lloyd J; Jackson K; Rublee D; Samore MH
    Ann Pharmacother; 2007 Mar; 41(3):400-6. PubMed ID: 17341537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.